Maddali DVM, Ph.D.
Cancer Genetics, Inc.
Dr. Kamala K Maddali holds a Ph.D., in Pharmacology from University of Missouri-Columbia and a DVM Veterinary Medicine from Acharya N.G. Ranga Agricultural University in India. Her innovative leadership acumen started over a decade ago with her pivotal role in Merck and Co as a biomarker scientist understanding the various pharmacological and toxic effects of the investigational novel drugs across multiple therapeutic areas in Oncology, Neurology and Obesity disorders. She has played various leadership roles as a “chief scientific commercial liaison” for clinical trial laboratory testing at top tier central laboratories and reference laboratories like Quintiles and Quest Diagnostics. Overall, she brings a lot of strategic values from her previous roles and also as an active speaker at various conferences worldwide for biomarkers and companion diagnostics. Her mantra for leadership is to “spread some sunshine” by being passionate and positive about her commitment to patient’s health via novel testing solutions. At Cancer Genetics, she has taken up a challenging role as “VP of Biopharma Collaborations’ to bring Innovation into CGI by expanding CGI Specialized Oncology testing into pharmaceutical novel clinical trials and also help pharma execute the innovative medicines to Oncology community. Cancer Genetics, Inc. (Nasdaq: CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and diagnostics announced today that it has developed and launched a comprehensive portfolio of tests and technologies to help measure and monitor immuno-oncology markers and select patients for targeted therapies. This portfolio will be available for clinical trials, patient care, and translational research utilizing multiple technological platforms and will be available at CGI’s New Jersey and Los Angeles facilities. In addition, the newly acquired Center of Excellence For Solid Tumor Testing based in Los Angeles, formerly Response Genetics, will also offer the FDA-approved PD-L1 antibody for selection of patients that are most likely to benefit from key immuno-oncology drugs. Immuno-oncology drugs by themselves have been shown to be highly effective in 20 to 30 percent of patients, and combination therapies are bringing the promise of more significant patient benefits. In order to develop more effective treatments with fewer side effects, immune-oncology biomarkers and tests helping to assess the effects of therapies will play a key role. Dr. Maddali is CGI’s Innovation hero and initiated an actively on-going “Biopharm Collaboration campaign” where she has implemented strategic initiatives to foster positive growth of the company through the provision of high-quality, innovative, responsive services. Her vision is to ensure that patient’s voice is heard and her goal is to help patients and pharma partners implement the right test for the right patient and innovate a right drug for improving global community health.